文献速递临床试验与 GCP流行病学与生物统计

低水平HIV-1病毒血症患者换用二线vs继续一线抗逆转录病毒治疗:莱索托开放标签随机对照试验

Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho.
PubMed 文献 · PLoS Med · 2020-09-16

该多中心开放标签优效性随机对照试验在莱索托8家诊所纳入80例一线NNRTI方案治疗、连续两次VL≥100 copies/mL且第二次100-999 copies/mL的患者,1:1随机换二线或继续一线。36周时换药组病毒抑制率55% vs 25%(调整差29%,95%CI 8%-50%,p=0.009),支持降低WHO病毒学失败阈值。

要点

  • 持续低水平病毒血症(100-999 copies/mL)换二线可提高36周病毒抑制率。
  • 换药组不良事件发生率更高(85% vs 53%,p=0.002),但无住院或死亡。
  • 结果支持未来WHO指南降低病毒学失败阈值。

核心结论

  • 持续低水平HIV-1病毒血症患者换用二线ART后36周病毒抑制比例更高。
  • 结果支持未来WHO指南降低病毒学失败阈值。

研究设计与样本

  • 多中心、平行组、开放标签、优效性随机对照试验,在莱索托8家诊所开展。
  • 纳入一线含NNRTI方案、连续两次VL≥100 copies/mL且第二次100-999 copies/mL的患者。
  • 共筛查137例,80例合格并1:1随机至换药组(n=40)或对照组(n=40),按机构、人群组和基线VL分层。
  • 主要终点为36周病毒抑制(<50 copies/mL),意向性分析,逻辑回归调整人群组和基线VL。

主要发现

  • 36周时换药组22/40(55%)vs对照组10/40(25%)达到病毒抑制(调整差29%,95%CI 8%-50%,p=0.009)。
  • 换药组在<20、<100、<200、<400和<600 copies/mL阈值下病毒抑制概率显著更高,但<1,000 copies/mL阈值下无显著差异。
  • 未观察到住院、死亡或其他严重不良事件。
  • 参与者多数为女性(54例,68%),中位年龄42岁(IQR 35-51),49例(61%)使用TDF/3TC/EFV,中位ART时间5.9年(IQR 3.3-8.6)。

关键数值与推荐

  • WHO现行指南定义病毒学失败为连续两次VL≥1,000 copies/mL,触发经验性换药。
  • 本试验入组标准为连续两次VL≥100 copies/mL且第二次100-999 copies/mL。
  • 主要终点病毒抑制定义为<50 copies/mL。

临床怎么用

  • 对一线ART持续低水平病毒血症(100-999 copies/mL)患者,可考虑换用二线ART以提高病毒抑制率。
  • 换药决策需权衡不良事件风险增加,尽管本试验未观察到严重不良事件。

局限性

  • 随访期过短,无法观察临床结局差异。
  • 研究期间国家试剂短缺导致CD4细胞计数缺失值。
  • 结果仅适用于NNRTI为基础的一线方案,外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current World Health Organization (WHO) antiretroviral therapy (ART) guidelines define virologic failure as two consecutive viral load (VL) measurements ≥1,000 copies/mL, triggering empiric switch to next-line ART. This trial assessed if patients with sustained low-level HIV-1 viremia on first-line ART benefit from a switch to second-line treatment. METHODS AND FINDINGS: This multicenter, parallel-group, open-label, superiority, randomized controlled trial enrolled patients on first-line ART containing non-nucleoside reverse transcriptase inhibitors (NNRTI) with two consecutive VLs ≥100 copies/mL, with the second VL between 100-999 copies/mL, from eight clinics in Lesotho. Consenting participants were randomly assigned (1:1), stratified by facility, demographic group, and baseline VL, to either switch to second-line ART (switch group) or continued first-line ART (control group; WHO guidelines). The primary endpoint was viral suppression (<50 copies/mL) at 36 weeks. Analyses were by intention to treat, using logistic regression models, adjusted for demographic group and baseline VL. Between August 1, 2017, and August 7, 2019, 137 individuals were screened, of whom 80 were eligible and randomly assigned to switch (n = 40) or control group (n = 40). The majority of participants were female (54 [68%]) with a median age of 42 y (interquartile range [IQR] 35-51), taking tenofovir disoproxil fumarate/lamivudine/efavirenz (49 [61%]) and on ART for a median of 5.9 y (IQR 3.3-8.6). At 36 weeks, 22/40 (55%) participants in the switch versus 10/40 (25%) in the control group achieved viral suppression (adjusted difference 29%, 95% CI 8%-50%, p = 0.009). The switch group had significantly higher probability of viral suppression across different VL thresholds (<20, <100, <200, <400, and <600 copies/mL) but not for <1,000 copies/mL. Thirty-four (85%) participants in switch group and 21 (53%) in control group experienced at least one adverse event (AE) (p = 0.002). No hospitalization or death or other serious adverse events were observed. Study limitations include a follow-up period too short to observe differences in clinical outcomes, missing values in CD4 cell counts due to national stockout of reagents during the study, and limited generalizability of findings to other than NNRTI-based first-line ART regimens. CONCLUSIONS: In this study, switching to second-line ART among patients with sustained low-level HIV-1 viremia resulted in a higher proportion of participants with viral suppression. These results endorse lowering the threshold for virologic failure in future WHO guidelines. TRIAL REGISTRATION: The trial is registered at ClinicalTrials.gov, NCT03088241.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Amstutz A, Nsakala BL, Vanobberghen F, et al. Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho. PLoS Med. 2020. PMID: 32936795. doi:10.1371/journal.pmed.1003325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。